Deciphering Your Pathology and Risk Scores

Your pathology report and risk scores are the tools your care team uses to move from a general diagnosis to a personalized treatment plan. These documents can be dense with technical language, but they essentially answer two main questions: “What does the bone marrow look like right now?” and “How is the disease likely to behave in the future?” ^[1][2]

Grading the Scar Tissue (Fibrosis)

When a pathologist looks at your bone marrow biopsy, they use a scale from MF-0 to MF-3 to grade the amount of reticulin (fiber) and collagen buildup ^[3]. This grading, combined with cellularity and megakaryocyte appearance, helps distinguish between the two main stages of primary myelofibrosis:

• MF-0 or MF-1 (Prefibrotic/Early PMF): The bone marrow shows minimal or no scarring. In this stage, the diagnosis is based more on the unusual shape and “clustering” of certain blood-forming cells ^[3][4].
• MF-2 or MF-3 (Overt PMF): These grades indicate significant, visible scarring. This stage is more likely to be associated with an enlarged spleen and lower blood counts ^[3][5].

Tracking “Blasts” and Disease Phases

Your blood and marrow reports will list a percentage of blasts, which are immature blood-forming cells ^[6]. In healthy marrow, blasts are rare. In myelofibrosis, the number of blasts helps define the “phase” of the disease:

• Chronic Phase: Most patients are diagnosed here. Blasts are low (typically below 10%) ^[6].
• Accelerated Phase: Blasts make up 10% to 19% of the blood or marrow. This indicates the disease is becoming more active ^[6][7].
• Blast Phase: Blasts reach 20% or higher. This is treated similarly to acute leukemia ^[6][5].

Even if your blasts are below 10%, a rise above 3% to 5% is often viewed as a prognostic warning used in some models rather than a universal phase-defining threshold, and your doctor will watch it closely ^[7][5].

Risk Scoring: Predicting the Future

Because myelofibrosis affects everyone differently, doctors use scoring systems to group patients into risk categories (Low, Intermediate-1, Intermediate-2, or High) ^[8]. These scores help determine if you should “watch and wait” or consider intensive treatments like a stem cell transplant ^[9].

Primary Myelofibrosis (PMF) Scores

• DIPSS and DIPSS-plus: These are clinical scores ^[8][10].
• MIPSS70 and MIPSS70-plus: These “molecular” scores are more modern. They combine clinical factors with your genetic mutation data, specifically looking for “high-molecular-risk” mutations which can make the disease more aggressive ^[11][5].

Secondary Myelofibrosis Score

• MYSEC-PM: This is the preferred score if your MF developed from Polycythemia Vera or Essential Thrombocythemia ^[12]. It weights factors differently to give a more accurate picture for secondary MF ^[12][13].

What Your Risk Category Means for You

These categories are population tools, not an individual deadline, but a guide for your doctor’s strategy:

• Low / Intermediate-1: If you have no symptoms, your doctor may recommend “watchful waiting” or simple symptom management ^[14]. Watchful waiting is an active management strategy, but does not mean you have an exact individual timeline; symptoms, trajectory, and patient goals affect the plan ^[10][15].
• Intermediate-2 / High: These categories suggest a more aggressive disease. For patients who are physically fit, this is often the point where an allogeneic stem cell transplant—the only potential cure—is discussed seriously ^[9][16].

If different scoring systems give you different risk levels, don’t panic. Your doctor will look at the “big picture” of your pathology, genetics, and how you feel to make the final recommendation ^[17].